A Closer Look at the Approval of CRISPR/Cas9 Gene Therapy for Sickle Cell Disease
(MedPage Today) -- On Friday, the FDA approved two gene therapies to treat patients with sickle cell disease (SCD). One of the therapies, called exagamglogene autotemcel (Casgevy), is the first FDA-approved gene therapy utilizing CRISPR/Cas9, a...
Source: MedPage Today Public Health - Category: American Health Source Type: news
More News: American Health | Gene Therapy | Genetics | International Medicine & Public Health | Sickle Cell Anemia